Ludwig researchers devise and test pioneering personalized ovarian cancer vaccine

(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.